Skip to main content
Aurobindo Pharma Ltd. logo

Aurobindo Pharma Ltd. — Investor Relations & Filings

Ticker · AUROPHARMA ISIN · INE406A01037 LEI · 335800G4T2A353RDGM23 BSE.NS Manufacturing
Open in API
Filings indexed 1,446 across all filing types
Latest filing 2026-05-24 Regulatory Filings
Country IN India
Listing BSE.NS AUROPHARMA

About Aurobindo Pharma Ltd.

https://www.aurobindo.com/

Aurobindo Pharma Ltd. focuses on the development, manufacturing, and commercialization of generic formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning key therapeutic areas, including antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, and anti-diabetics. With a strong emphasis on vertical integration, the organization manages a comprehensive supply chain from basic chemicals to finished dosage forms. It operates advanced research and development centers and manufacturing facilities that comply with international regulatory standards. The company serves a broad international market, providing cost-effective healthcare solutions through an extensive pipeline of Abbreviated New Drug Applications (ANDAs) and a robust distribution network.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 80% confidence The document is an exchange filing under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, notifying the stock exchanges of a regulatory inspection outcome (US FDA’s OAI classification) for a subsidiary facility. It does not contain financial data or act as an interim or annual report, nor is it a proxy, dividend notice, or earnings release. This type of miscellaneous regulatory disclosure fits the "Regulatory Filings" category (RNS).
2026-05-24 English
Intimation of classification of Unit-1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
Regulatory Filings Classification · 87% confidence The document is a formal disclosure to Indian stock exchanges under SEBI LODR Regulation 30, informing of an FDA inspection outcome (OAI) at a wholly-owned subsidiary. It is not a financial report, management change, capital action, or earnings release but a regulatory/compliance announcement. It does not itself contain financial statements or substantive report content, nor is it a proxy or dividend notice. This is a general regulatory announcement, so it falls under Regulatory Filings (RNS).
2026-05-24 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 89% confidence The document is a brief notice to the stock exchanges stating that the company has published its quarterly and full‐year financial results in newspaper advertisements and enclosing copies of those ads. It does not itself contain any financial data or detailed results—it simply announces the publication of the report. Under the “menu vs. meal” rule, this is an announcement that a report has been published, making it a Report Publication Announcement (RPA).
2026-05-23 English
Submission of copies of financial results published in newspapers.
Report Publication Announcement Classification · 85% confidence The document is a brief letter from the company secretary to stock exchanges stating that newspaper advertisements containing the financial results for the quarter and year ended March 31, 2026, have been published and are enclosed. It contains no substantive financial data itself but simply announces the publication of the results. According to the “menu vs meal” rule, this is a Report Publication Announcement (RPA).
2026-05-23 English
Intimation of incorporation of a new stepdown subsidiary in France.
Regulatory Filings Classification · 82% confidence The document is a statutory disclosure under Regulation 30 of SEBI listing rules, notifying stock exchanges of the incorporation of a wholly-owned step-down subsidiary and providing details of share subscription and capital. It is not a full financial report, management presentation, dividend notice, or proxy. It is a routine regulatory announcement under listing obligations and best fits the generic Regulatory Filings (RNS) category.
2026-05-22 English
Acquisition
Regulatory Filings Classification · 94% confidence The document is a compliance announcement under Regulation 30 of the SEBI (LODR) Regulations notifying the exchange of incorporation of a new wholly owned subsidiary. It is a regulatory disclosure to the stock exchanges, not a full financial report, earnings release, or corporate governance document. It fits the general category of a regulatory filing/disclosure announcement. Therefore, it is classified as RNS (Regulatory Filings).
2026-05-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.